Etana to Produce Cancer Drug after Securing Funding from DEG

blood sample test

Biopharmaceutical startup PT Etana Biotechnologies Indonesia (Etana) raised undisclosed funding from DEG, Yunfeng Capital, HighLight Capital, and East Ventures.

Etana President Director Nathan Tritana said with this funding, Etana aims to offer high-quality, innovative, and affordable biopharmaceutical products to Indonesia and other Southeast Asian countries. Etana plans to utilize the funds to establish local biopharmaceutical production capabilities.

Wilson Cuaca, East Ventures' co-founder and managing partner, said the COVID-19 pandemic had exposed the weakness of Indonesia's healthcare system.

Hence, all stakeholders must devise innovative and rapid solutions to address this health crisis. "Etana's products, such as vaccines, have augmented the national healthcare system's strength and resilience," he said.

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.